NextCure Inc (NXTC)
NASDAQ:NXTC
Top Page
NextCure
(NASDAQ:NXTC)
Select Model
Select Model
Rating:54Neutral
Price Target:
$11.00
▼(-19.88% Downside)
Action:ReiteratedDate:03/06/26
Overall score is held back primarily by weak financial performance (no revenue, ongoing losses and cash burn, and reduced equity), partially offset by a moderately positive technical trend and supportive pipeline/runway updates. Valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Advancing ADC clinical programs
Advancing two ADC programs through Phase 1 dose-escalation (SIM0505 and LNCB74) creates durable R&D value drivers: upcoming SIM0505 data and broader enrollment for LNCB74 can materially de-risk assets, enable partnering/licensing opportunities, and support long-term pipeline value if signals are positive.
Negative Factors
Pre-revenue, persistent losses
The company remains pre-revenue with substantial recurring net losses, meaning sustainable operations depend on external capital. Persistent negative profitability limits reinvestment capacity and increases long-term execution risk if clinical programs do not produce value-driving outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Advancing ADC clinical programs
Advancing two ADC programs through Phase 1 dose-escalation (SIM0505 and LNCB74) creates durable R&D value drivers: upcoming SIM0505 data and broader enrollment for LNCB74 can materially de-risk assets, enable partnering/licensing opportunities, and support long-term pipeline value if signals are positive.
Read all positive factors
NextCure (NXTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$41.44M
Dividend YieldN/A
Average Volume (3M)37.58K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth3.78%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding3,560,410
10 Day Avg. Volume95,061
30 Day Avg. Volume37,578
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.38
Enterprise Value/Ebitda-0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-7.91
Revenue Forecast (FY)N/A
NextCure Business Overview & Revenue Model
Company Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, whi...
How the Company Makes Money
NextCure’s primary source of cash flows is funding from financing activities (e.g., issuing equity or other capital-raising transactions) because it is a clinical-stage company and does not have product sales from approved therapies. Operating rev...
NextCure Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.19M | -2.87M | 0.00 | 0.00 | 0.00 |
| EBITDA | -55.43M | -54.34M | -63.95M | -71.78M | -66.59M |
| Net Income | -55.84M | -55.65M | -62.72M | -74.73M | -69.39M |
Balance Sheet | |||||
| Total Assets | 50.18M | 80.86M | 128.04M | 184.16M | 242.39M |
| Cash, Cash Equivalents and Short-Term Investments | 41.82M | 68.62M | 108.30M | 159.91M | 219.59M |
| Total Debt | 4.15M | 5.95M | 6.61M | 7.12M | 0.00 |
| Total Liabilities | 15.24M | 15.39M | 13.62M | 16.63M | 9.00M |
| Stockholders Equity | 34.94M | 65.47M | 114.42M | 167.53M | 233.39M |
Cash Flow | |||||
| Free Cash Flow | -49.61M | -41.28M | -53.79M | -56.00M | -59.60M |
| Operating Cash Flow | -49.61M | -40.80M | -52.97M | -53.89M | -57.24M |
| Investing Cash Flow | 25.56M | 55.31M | 39.27M | 67.98M | 36.60M |
| Financing Cash Flow | 22.31M | 144.00K | 154.00K | 200.00K | -3.27M |
NextCure Technical Analysis
Positive
13.73
Price Trends
11.83
Negative
12.04
Negative
9.21
Positive
Market Momentum
-0.24
Negative
54.30
Neutral
76.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXTC, the sentiment is Positive. The current price of 13.73 is above the 20-day moving average (MA) of 10.87, above the 50-day MA of 11.83, and above the 200-day MA of 9.21, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 54.30 is Neutral, neither overbought nor oversold. The STOCH value of 76.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NXTC.
NextCure Risk Analysis
NextCure disclosed 70 risk factors in its most recent earnings report. NextCure reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NextCure Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $41.44M | -0.72 | -152.90% | ― | ― | 3.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $7.41M | -5.72 | -9.02% | ― | ― | -1979.68% | |
45 Neutral | $7.18M | -2.52 | -229.48% | ― | ― | 71.57% | |
44 Neutral | $238.44M | -0.04 | 506.72% | ― | ― | -323.61% | |
41 Neutral | $7.25M | -0.33 | -925.11% | ― | ― | ― |
* Healthcare Sector Average
NXTC
NextCure
11.64
7.90
211.23%
NERV
Minerva Neurosciences
5.51
3.94
251.63%
MTVA
MetaVia
1.41
-18.83
-93.03%
ATON
AlphaTON Capital
0.31
-8.57
-96.52%
APM
Aptorum Group
0.91
0.09
10.98%
NextCure Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
NextCure Updates ADC Pipeline Progress and Cash Runway
Positive
Jan 23, 2026
On January 23, 2026, NextCure reported program and financial updates, highlighting progress in its two antibody-drug conjugate candidates and outlining its cash position. The company plans to present Phase 1 dose-escalation data for SIM0505, a cad...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.